The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chutko L.S.

N.P. Bechtereva Institute of the Human Brain of the Russian Academy of Sciences;
Saint-Petersburg State Pediatric Medical University

Yakovenko E.A.

N. Bekhtereva Institute of Human Brain Russian Academy of Sciences

Surushkina S.Yu.

N. Bekhtereva Institute of Human Brain Russian Academy of Sciences

From Little to Great

Authors:

Chutko L.S., Yakovenko E.A., Surushkina S.Yu.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2025;(5‑6): 76‑80

Read: 175 times

Buy for 300₽
Contact the author
Table of contents

To cite this article:

Chutko LS, Yakovenko EA, Surushkina SYu. From Little to Great. Non Nocere. New Therapeutic Journal. 2025;(5‑6):76‑80. (In Russ.)

 
 
ЭндоКард
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

Attention deficit hyperactivity disorder: clinical manifestations from child to adult.

Authors:

Chutko L.S.

N.P. Bechtereva Institute of the Human Brain of the Russian Academy of Sciences;
Saint-Petersburg State Pediatric Medical University

Yakovenko E.A.

N. Bekhtereva Institute of Human Brain Russian Academy of Sciences

Surushkina S.Yu.

N. Bekhtereva Institute of Human Brain Russian Academy of Sciences

Close metadata

References:

  1. Saint-Exupery A. The Little Prince : with illustrations by the author: per. from Fr. Moscow : International Relations, 1996.
  2. Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015 Apr;135(4): e994-1001. https://doi.org/10.1542/peds.2014-3482
  3. Bitsko RH, Claussen AH, Lichstein J, et al. Contributor. Mental Health Surveillance Among Children – United States, 2013-2019. MMWR Suppl. 2022 Feb 25;71(2):1-42.  https://doi.org/10.15585/mmwr.su7102a1
  4. Reuben C, Elgaddal N. Attention-Deficit/Hyperactivity Disorder in Children Ages 5-17 Years: United States, 2020-2022. NCHS Data Brief. 2024 Mar;(499):1-9. 
  5. Skogli EW, Teicher MH, Andersen PN, et al. ADHD in girls and boys – gender differences in co-existing symptoms and executive function measures. BMC Psychiatry. 2013;13:298. http://www.biomedcentral.com/1471-244X/13/298 
  6. Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018 Feb;5(2):175-186.  https://doi.org/10.1016/S2215-0366(17)30167-0
  7. Barkley RA. Attention-deficit hyperactivity disorder. Sci Am. 1998 Sep;279(3):66-71.  https://doi.org/10.1038/scientificamerican0998-66
  8. O’Neill S, Rajendran K, Mahbubani SM, Halperin JM. Preschool Predictors of ADHD Symptoms and Impairment During Childhood and Adolescence. Curr Psychiatry Rep. 2017 Oct 30;19(12):95.  https://doi.org/10.1007/s11920-017-0853-z
  9. Lawrence D, Houghton S, Dawson V, Sawyer M, Carroll A. Trajectories of academic achievement for students with attention-deficit/hyperactivity disorder. Br J Educ Psychol. 2021 Jun;91(2):755-774.  https://doi.org/10.1111/bjep.12392
  10. Zavadenko N.N. Hyperactivity and attention deficit in childhood / Study guide. – Moscow: Academy, 2005. – 255 p. 
  11. Mrug S, Molina BS, Hoza B, et al. Peer rejection and friendships in children with Attention-Deficit/Hyperactivity Disorder: contributions to long-term outcomes. J Abnorm Child Psychol. 2012 Aug;40(6):1013-1026. https://doi.org/10.1007/s10802-012-9610-2
  12. Hoza B, Mrug S, Gerdes AC, et al. What aspects of peer relationships are impaired in children with attention-deficit/hyperactivity disorder? J Consult Clin Psychol. 2005 Jun;73(3):411-423.  https://doi.org/10.1037/0022-006X.73.3.411
  13. Friedel E, Vijayakumar N, Staniland L, Silk T. Puberty and ADHD: A scoping review and framework for future research. Clin Psychol Rev. 2025;117:102567. https://doi.org/10.1016/j.cpr.2025.102567
  14. Karteczka-Świętek K, Opozda-Suder S, Strojny A. Psychosocial functioning of adolescents with ADHD in the family, school and peer group: A scoping review protocol. PLoS One. 2022 Jun 17;17(6): e0269495. https://doi.org/10.1371/journal.pone.0269495
  15. Kooij JJS, Bijlenga D, Salerno L, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019 Feb;56:14-34.  https://doi.org/10.1016/j.eurpsy.2018.11.001
  16. Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I. The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. J Glob Health. 2021 Feb 11;11:04009. https://doi.org/10.7189/jogh.11.04009
  17. Faheem M, Akram W, Akram H, Khan MA, Siddiqui FA, Majeed I. Gender-based differences in prevalence and effects of ADHD in adults: A systematic review. Asian J Psychiatr. 2022 Sep;75:103205. https://doi.org/10.1016/j.ajp.2022.103205
  18. Hupfeld KE, Abagis TR, Shah P. Living «in the zone»: hyperfocus in adult ADHD. ADHD Atten Def Hyp Disord. 2019;11(2):191-208.  https://doi.org/10.1007/s12402-018-0272-y
  19. Groen Y, Priegnitz U, Fuermaier ABM, et al. Testing the relation between ADHD and hyperfocus experiences. Res Dev Disabil. 2020 Dec;107:103789. https://doi.org/10.1016/j.ridd.2020.103789
  20. Chutko LS, Surushkina SYu, Iakovenko EA, Nikishena IS, Anisimova TI. Attention deficit syndrome in adults: clinical, psychophysiological features and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(8):38-41. (In Russ.) https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2013/8/031997-7298201386
  21. Hirsch O, Chavanon M, Riechmann E, Christiansen H. Emotional dysregulation is a primary symptom in adult Attention-Deficit/Hyperactivity Disorder (ADHD). J Affect Disord. 2018 May;232:41-47.  https://doi.org/10.1016/j.jad.2018.02.007
  22. Shapero BG, Gibb BE, Archibald A, Wilens TE, Fava M, Hirshfeld-Becker DR. Risk Factors for Depression in Adolescents With ADHD: The Impact of Cognitive Biases and Stress. J Atten Disord. 2021 Feb;25(3):340-354.  https://doi.org/10.1177/1087054718797447
  23. Bob P, Privara M. ADHD, stress, and anxiety. Front Psychiatry. 2025 Mar 18;16:1536207. https://doi.org/10.3389/fpsyt.2025.1536207
  24. Fitzgerald C, Dalsgaard S, Nordentoft M, Erlangsen A. Suicidal behaviour among persons with attention-deficit hyperactivity disorder. Br J Psychiatry. 2019 Jun 7:1-6.  https://doi.org/10.1192/bjp.2019.128
  25. Zulauf CA, Sprich SE, Safren SA, Wilens TE. The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Curr Psychiatry Rep. 2014 Mar;16(3):436.  https://doi.org/10.1007/s11920-013-0436-6
  26. Adamou M, Arif M, Asherson P, et al. Occupational issues of adults with ADHD. BMC Psychiatry. 2013 Feb 17;13:59.  https://doi.org/10.1186/1471-244X-13-59
  27. Bangma DF, Tucha L, Fuermaier ABM, Tucha O, Koerts J. Financial decision-making in a community sample of adults with and without current symptoms of ADHD. PLoS One. 2020 Oct 12;15(10): e0239343. https://doi.org/10.1371/journal.pone.0239343
  28. Altszuler AR, Page TF, Gnagy EM, et al. Financial Dependence of Young Adults with Childhood ADHD. J Abnorm Child Psychol. 2016 Aug;44(6):1217-1229. https://doi.org/10.1007/s10802-015-0093-9
  29. Ginsberg Y, Hirvikoski T, Lindefors N. Attention Deficit Hyperactivity Disorder (ADHD) among longer-term prison inmates is a prevalent, persistent and disabling disorder. BMC Psychiatry. 2010 Dec 22;10:112.  https://doi.org/10.1186/1471-244X-10-112
  30. Freckelton I. Attention Deficit Hyperactivity Disorder (ADHD) and the Criminal Law. Psychiatr Psychol Law. 2020 Jan 6;26(6):817-840.  https://doi.org/10.1080/13218719.2019.1695266
  31. Fuermaier AB, Tucha L, Evans BL, et al. Driving and attention deficit hyperactivity disorder. J Neural Transm (Vienna). 2017 Feb;124(Suppl 1):55-67.  https://doi.org/10.1007/s00702-015-1465-6
  32. Bron TI, Bijlenga D, Breuk M, Michielsen M, Beekman ATF, Kooij JJS. Risk factors for adverse driving outcomes in Dutch adults with ADHD and controls. Accid Anal Prev. 2018 Feb;111:338-344.  https://doi.org/10.1016/j.aap.2017.12.011
  33. O’Nions E, El Baou C, John A, et al. Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study. Br J Psychiatry. 2025 Jan 23:1-8.  https://doi.org/10.1192/bjp.2024.199
  34. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep;128:789-818.  https://doi.org/10.1016/j.neubiorev.2021.01.022
  35. Coghill D, Banaschewski T, Cortese S, et al. The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). Eur Child Adolesc Psychiatry. 2023 Aug;32(8):1337-1361. https://doi.org/10.1007/s00787-021-01871-x
  36. Hyperactive children: psychological and pedagogical help : a monograph / L.S. Chutko, G.B. Monina, E.K. Lyutova-Roberts. – SPb. : Rech, 2007. — 186 p. 
  37. Hirvikoski T, Waaler E, Lindström T, Bölte S, Jokinen J. Cognitive behavior therapy-based psychoeducational groups for adults with ADHD and their significant others (PEGASUS): an open clinical feasibility trial. Atten Defic Hyperact Disord. 2015 Mar;7(1):89-99.  https://doi.org/10.1007/s12402-014-0141-2
  38. Cognitive behavioral therapy of mental disorders / Praszko J., Można P., Šlepecki M., et al. – M. : IOI, 2015. – 1072 p. 
  39. Zavadenko N.N., Suvorinova N.Yu., Zavadenko A.N. Attention deficit hyperactivity disorder in children: effectiveness of hopantenic acid pharmacotherapy. Vopr. prakt. pediatr. (Clinical Practice in Pediatrics). 2018; 13(2): 11–18. (In Russ.) https://doi.org/10.20953/1817-7646-2018-2-11-18
  40. Zavadenko NN, Makushkin EV, Gaynetdinova DD, et al. Treatment of attention deficit hyperactivity disorder in children: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11):62-68. (In Russ.) https://doi.org/10.17116/jnevro202212211162
  41. Zykov VP, Serebrennikova EB, Panchenko TN, et al. Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3):27-31. (In Russ.) https://doi.org/10.17116/jnevro20181183127-31
  42. Goriunova AV, Shevchenko IuS, Goriunov AV. Cogitum in children’s neurology and psychiatry (experience in the practical use). S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7-2):58-66. (In Russ.) https://doi.org/10.17116/jnevro201911907258
  43. Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3-2):55-65. (In Russ., In Engl.) https://doi.org/10.17116/jnevro20171173255-65
  44. Chukhlovina ML, Chukhlovin AA. Features of the patient management with traumatic brain injury. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9):145-151. (In Russ.) https://doi.org/10.17116/jnevro2021121091145
  45. Fedin AI, Zaharov VV, Tanashyan MM, Chukanova EI, Madzhidova EN, Shchepankevich LA, Ostroumova OD. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7-16. (In Russ., In Engl.) https://doi.org/10.17116/jnevro20211211117
  46. General description of the medicinal product Mexidol film-coated tablets, 125 mg. LP-No.(000086)-(RG-RU) dated 08.02.2023.
  47. Zavadenko NN, Suvorinova NYu, Batysheva TT, et al. Results of a multicentre double-blind randomised placebo-controlled clinical trial evaluating the efficacy and safety of Mexidol in the treatment of Attention Deficit Hyperactivity Disorder in Children (MEGA). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(4):75-86. (In Russ., In Engl.) https://doi.org/10.17116/jnevro202212204175
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.